Taken together, our research demonstrates that MARCO blockade may be used as a tactic to increase the efficacy of treatments that target the adaptive branch of the immune response, supporting and expanding the application of immune checkpoint therapy in RCC. This evidence concerns the gene MARCO and renal cell carcinoma.